MacroGenics Secures $182.5M Non-Dilutive Cash, Extends Runway to 2028
MGNX•MacroGenics reported a narrower Q1 2026 net loss of $0.58 per share versus $0.65 in Q1 2025, slightly ahead of the estimated $0.57 loss. The company secured $122.5 million upfront from a sale of its manufacturing operations and $60 million from expanded ZYNYZ royalty monetization, extending cash runway through 2028.
1. Q1 2026 Financial Results
MacroGenics reported a net loss of $0.58 per share for the quarter ended March 31, 2026, compared with a $0.65 per share loss in Q1 2025. The result modestly beat analyst expectations and laid the groundwork for the company’s strategic transformation.
2. Manufacturing Operations Divestiture
The company entered into a definitive agreement to sell its GMP manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million before fees, with closing expected in Q3 2026. A supply agreement will ensure continued clinical drug substance production under an outsourced model.
3. ZYNYZ Royalty Monetization
MacroGenics amended its royalty purchase agreement to receive $60 million in upfront cash from Sagard Healthcare Partners in exchange for a capped future royalty interest on ZYNYZ global net sales. The deal includes a milestone payment of up to $20 million based on 2026 sales performance.
4. Pipeline Advancement and Cash Runway
The company’s ADC pipeline remains on track, with initial Phase 1 data for MGC026 due mid-2026, MGC028 data in H2 2026, and an IND filing for MGC030 planned in Q3 2026. Non-dilutive proceeds and operational savings are projected to extend the cash runway through 2028.
